Zymeworks

ZLAB Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$20.41

+0.34% today

52W: $15.96 – $44.34

52W Low: $15.96 Position: 15.7% 52W High: $44.34

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

5.01x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$2.3B

Market Capitalization

Revenue Growth

17%

YoY Revenue Growth

Profit Margin

-38.15%

Net profit margin

ROE

-22.56%

Return on Equity

Beta

0.86

Market sensitivity

Short Interest

4.94%

% of float sold short

Avg. Volume

744,021

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

11 analysts

Avg. Price Target

$38.47

+88.47% upside

Target Range

$21.80 – $55.00

About the Company

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoacet

Sector: Healthcare Industry: Biotechnology Country: China Employees: 1,784 Exchange: NGM